The next generation of computational and modeling approaches should include data that model the effects of formulation composition on solution and protein properties, including viscosity, rather than predicting viscosity at single, static conditions
It is believed to trigger the migration of cells to the site of injury, encourage angiogenesis (the creation of new blood vessels), and control inflammation to promote the healing process
31 ElsonELQianHFeeJAWakatsukiT
We incorporate these findings into a broader model of GLP1 medication response, and demonstrate the ability to stratify patients by efficacy and side effect risk
Approval: 1978 Indications and Usage for DDAVP Nasal Spray DDAVP Nasal Spray is a vasopressin analog indicated as antidiuretic replacement therapy in the management of central diabetes insipidus for adults and pediatric patients 4 years of age and older (1) Limitations of Use: DDAVP Nasal Spray is not indicated for: Treatment of nephrogenic diabetes insipidus (1) Treatment of primary nocturnal enuresis (1, 5.1) Use in patients with conditions that compromise intranasal route of administration (1, 5.2) Use in patients with an impaired level of consciousness (1) Use in patients requiring doses less than 10 mcg or doses that are not multiples of 10 mcg (1,3) DDAVP Nasal Spray Dosage and Administration For intranasal use only (2.1) Instruct patients to prime pump prior to use (2.1) Adults: 10 mcg to 40 mcg daily (either as a single dose or divided into two or three daily doses) (2.2) Pediatrics: 10 mcg once daily into one nostril up to 30 mcg once daily (or 30 mcg divided as 20 mcg during the morning and 10 mcg at night) (2.2) See the Full Prescribing Information for recommendations for switching between desmopressin acetate formulations (2.3) Dosage Forms and Strengths Nasal Spray: 10 mcg per 0.1 mL spray, available in a 5 mL bottle with spray pump delivering 50 sprays (3) Contraindications Warnings and Precautions Adverse Reactions/Side Effects Adverse reactions that have been identified in patients administered DDAVP Nasal Spray are headache, nasal congestion, rhinitis, nosebleed, sore throat, cough, upper respiratory infections, nausea, flushing, and mild abdominal cramps (6) To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals Inc
You feel this as fatigue, brain fog, and joint pain
